<- Go Home
Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Market Cap
CHF 22.7B
Volume
478.9K
Cash and Equivalents
CHF 385.0M
EBITDA
CHF 841.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CHF 3.0B
Profit Margin
69.54%
52 Week High
CHF 98.02
52 Week Low
CHF 68.63
Dividend
N/A
Price / Book Value
2.97
Price / Earnings
-38.2K
Price / Tangible Book Value
-9.58
Enterprise Value
CHF 25.2B
Enterprise Value / EBITDA
29.03
Operating Income
CHF 626.8M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
CHF 385.0M
Debt
CHF 2.9B
Equity
CHF 7.6B
Revenue
CHF 4.3B
Unlevered FCF
N/A
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium